Qulipta

Chemical Nameatogepant
Dosage FormTablet (oral; 10 mg, 30 mg, 60 mg)
Drug ClassReceptor antagonists
SystemNervous
CompanyAbbvie Inc.
Approval Year2021

Indication

  • For the preventive treatment of episodic migraine in adults.
Last updated on 11/30/2021

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Qulipta (atogepant) Prescribing Information2021Forest Laboratories Ireland Ltd., Dublin, Ireland